QRxPharma has signed a contract with Patheon to manufacture clinical supplies of QRxPharma’s controlled release Dual-Opioid formulation, MoxDuoCR. MoxDuoCR is designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). “The Patheon relationship represents a major step forward for QRxPharma that rounds out our platform of MoxDuo products,” said Dr. John Holaday, QRxPharm...